{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:03:09Z","timestamp":1791489789888,"version":"4.3.4"},"reference-count":268,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100019779","name":"Qatar National Library","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019779","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Cancer Biology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.semcancer.2025.10.003","type":"journal-article","created":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T01:34:41Z","timestamp":1761356081000},"page":"1-22","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Beyond cardiovascular health: The pharmacotherapeutic potential of statins in oncology"],"prefix":"10.1016","volume":"117","author":[{"given":"Alaa","family":"Abdelhamid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dima","family":"Nasrallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esraa","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8656-1444","authenticated-orcid":false,"given":"Amirhossein","family":"Sahebkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali H.","family":"Eid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.semcancer.2025.10.003_bib1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2174\/1874467209666160112123746","article-title":"Mevalonate cascade and its regulation in cholesterol metabolism in different tissues in health and disease","volume":"10","author":"Hashemi","year":"2017","journal-title":"Curr. Mol. Pharm."},{"issue":"12","key":"10.1016\/j.semcancer.2025.10.003_bib2","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/0300-9084(94)90044-2","article-title":"Synthesis and function of isopentenyl adenosine derivatives in tRNA","volume":"76","author":"Persson","year":"1994","journal-title":"Biochimie"},{"issue":"1","key":"10.1016\/j.semcancer.2025.10.003_bib3","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1080\/10409238.2019.1568964","article-title":"Inhibition of farnesyl pyrophosphate (FPP) and\/or geranylgeranyl pyrophosphate (GGPP) biosynthesis and its implication in the treatment of cancers","volume":"54","author":"Waller","year":"2019","journal-title":"Crit. Rev. Biochem Mol. Biol."},{"issue":"12","key":"10.1016\/j.semcancer.2025.10.003_bib4","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.tem.2019.08.009","article-title":"The complexity of making ubiquinone","volume":"30","author":"Wang","year":"2019","journal-title":"Trends Endocrinol. Metab."},{"issue":"48","key":"10.1016\/j.semcancer.2025.10.003_bib5","doi-asserted-by":"crossref","first-page":"19074","DOI":"10.1021\/acs.analchem.4c04286","article-title":"Characterization of cell surface glycoproteins using enzymatic treatment and mass spectrometry","volume":"96","author":"Lin","year":"2024","journal-title":"Anal. Chem."},{"issue":"1","key":"10.1016\/j.semcancer.2025.10.003_bib6","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1046\/j.1432-1327.1999.00815.x","article-title":"Farnesylation of ras is important for the interaction with phosphoinositide 3-kinase gamma","volume":"266","author":"Rubio","year":"1999","journal-title":"Eur. J. Biochem"},{"issue":"37","key":"10.1016\/j.semcancer.2025.10.003_bib7","doi-asserted-by":"crossref","first-page":"25150","DOI":"10.1074\/jbc.M800882200","article-title":"Rho family GTPase modification and dependence on CAAX motif-signaled posttranslational modification","volume":"283","author":"Roberts","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.semcancer.2025.10.003_bib8","article-title":"Treasure island (FL)","author":"Huff","year":"2025","journal-title":"Physiol. Cholest. StatPearls"},{"issue":"11","key":"10.1016\/j.semcancer.2025.10.003_bib9","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1186\/gb-2004-5-11-248","article-title":"The 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductases","volume":"5","author":"Friesen","year":"2004","journal-title":"Genome Biol."},{"issue":"12","key":"10.1016\/j.semcancer.2025.10.003_bib10","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/nrendo.2017.91","article-title":"SREBP-regulated lipid metabolism: convergent physiology - divergent pathophysiology","volume":"13","author":"Shimano","year":"2017","journal-title":"Nat. Rev. Endocrinol."},{"issue":"9-10","key":"10.1016\/j.semcancer.2025.10.003_bib11","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.clinbiochem.2007.03.016","article-title":"Mevalonate pathway: a review of clinical and therapeutical implications","volume":"40","author":"Buhaescu","year":"2007","journal-title":"Clin. Biochem"},{"issue":"11","key":"10.1016\/j.semcancer.2025.10.003_bib12","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.012924","article-title":"Cholesterol and atherosclerotic cardiovascular disease: a lifelong problem","volume":"8","author":"Gidding","year":"2019","journal-title":"J. Am. Heart Assoc."},{"issue":"3","key":"10.1016\/j.semcancer.2025.10.003_bib13","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11906-020-1022-z","article-title":"Estrogen and bisphenol a in hypertension","volume":"22","author":"Wehbe","year":"2020","journal-title":"Curr. Hypertens. Rep."},{"key":"10.1016\/j.semcancer.2025.10.003_bib14","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.atherosclerosis.2022.08.012","article-title":"Role of RhoA and Rho-associated kinase in phenotypic switching of vascular smooth muscle cells: implications for vascular function","volume":"358","author":"Sawma","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.semcancer.2025.10.003_bib15","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.pcad.2024.10.009","article-title":"Revisiting high-density lipoprotein cholesterol in cardiovascular disease: is too much of a good thing always a good thing?","volume":"87","author":"Al Zein","year":"2024","journal-title":"Prog. Cardiovasc Dis."},{"issue":"8","key":"10.1016\/j.semcancer.2025.10.003_bib16","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.clinthera.2013.06.019","article-title":"New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes","volume":"35","author":"Sahebkar","year":"2013","journal-title":"Clin. Ther."},{"issue":"6","key":"10.1016\/j.semcancer.2025.10.003_bib17","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s10557-013-6479-4","article-title":"New therapies targeting apob metabolism for high-risk patients with inherited dyslipidaemias: what can the clinician expect?","volume":"27","author":"Sahebkar","year":"2013","journal-title":"Cardiovasc Drugs Ther."},{"issue":"5","key":"10.1016\/j.semcancer.2025.10.003_bib18","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s40256-023-00594-5","article-title":"Established and emerging Lipid-Lowering drugs for primary and secondary cardiovascular prevention","volume":"23","author":"Michaeli","year":"2023","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"10.1016\/j.semcancer.2025.10.003_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108507","article-title":"Beyond statins: new pharmacological targets to decrease LDL-cholesterol and cardiovascular events","volume":"250","author":"Raschi","year":"2023","journal-title":"Pharmacol. Ther."},{"issue":"36","key":"10.1016\/j.semcancer.2025.10.003_bib20","doi-asserted-by":"crossref","first-page":"7427","DOI":"10.2174\/0929867328666210222092628","article-title":"Lipid-Lowering therapies for atherosclerosis: statins, fibrates, ezetimibe and PCSK9 monoclonal antibodies","volume":"28","author":"Ali","year":"2021","journal-title":"Curr. Med Chem."},{"issue":"4","key":"10.1016\/j.semcancer.2025.10.003_bib21","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1582-4934.2001.tb00172.x","article-title":"Statins: mechanism of action and effects","volume":"5","author":"Stancu","year":"2001","journal-title":"J. Cell Mol. Med"},{"issue":"1","key":"10.1016\/j.semcancer.2025.10.003_bib22","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.pharmthera.2014.02.007","article-title":"Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease","volume":"143","author":"Yeganeh","year":"2014","journal-title":"Pharm. Ther."},{"key":"10.1016\/j.semcancer.2025.10.003_bib23","doi-asserted-by":"crossref","unstructured":"A.T. Bahar, T. Caner, A. Elif, T. \u0130stemihan, R.R. Nicolas, F. Gokhan, S.-F. K\u00fcbra, U. Tugce, G. Guido, F. Francesco, <p>Effects of Different Forms of Statins on Lipid Profile in Hyperlipidemic Patients<\/p>, Int. J. Pharmacol. 19(5).","DOI":"10.3923\/ijp.2023.708.713"},{"key":"10.1016\/j.semcancer.2025.10.003_bib24","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.ihj.2023.11.267","article-title":"Role of statins in the management of dyslipidaemia","volume":"76","author":"Ray","year":"2024","journal-title":"Indian Heart J."},{"key":"10.1016\/j.semcancer.2025.10.003_bib25","series-title":"Lipoproteins in Diabetes Mellitus","first-page":"579","article-title":"Statin therapy: impact on dyslipidemia and cardiovascular events in patients with diabetes","author":"Gudenkauf","year":"2023"},{"issue":"1","key":"10.1016\/j.semcancer.2025.10.003_bib26","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11883-024-01265-9","article-title":"Statin therapy in primary and secondary cardiovascular disease prevention","volume":"27","author":"Paparodis","year":"2024","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/j.semcancer.2025.10.003_bib27","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.phrs.2018.08.014","article-title":"Effect of statins on toll-like receptors: a new insight to pleiotropic effects","volume":"135","author":"Bahrami","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.semcancer.2025.10.003_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155659","article-title":"Ferroptosis, a new pathogenetic mechanism in cardiometabolic diseases and cancer: is there a role for statin therapy?","volume":"146","author":"Sahebkar","year":"2023","journal-title":"Metab. Clin. Exp."},{"issue":"2","key":"10.1016\/j.semcancer.2025.10.003_bib29","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.atherosclerosis.2015.05.022","article-title":"Statin therapy reduces plasma endothelin-1 concentrations: a meta-analysis of 15 randomized controlled trials","volume":"241","author":"Sahebkar","year":"2015","journal-title":"Atherosclerosis"},{"issue":"5","key":"10.1016\/j.semcancer.2025.10.003_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11051313","article-title":"Antioxidant effects of statins by modulating Nrf2 and Nrf2\/HO-1 signaling in different diseases","volume":"11","author":"Mansouri","year":"2022","journal-title":"J. Clin. Med."},{"issue":"6","key":"10.1016\/j.semcancer.2025.10.003_bib31","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1007\/s00204-023-03492-6","article-title":"Understanding the molecular mechanisms of statin pleiotropic effects","volume":"97","author":"German","year":"2023","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.semcancer.2025.10.003_bib32","doi-asserted-by":"crossref","first-page":"1188926","DOI":"10.3389\/fphar.2023.1188926","article-title":"New insights into the therapeutic potentials of statins in cancer","volume":"14","author":"Liu","year":"2023","journal-title":"Front Pharm."},{"issue":"12","key":"10.1016\/j.semcancer.2025.10.003_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2020.165968","article-title":"Pleiotropic effects of statins: a focus on cancer","volume":"1866","author":"Ahmadi","year":"2020","journal-title":"Biochim. Et. Biophys. Acta (BBA) Mol. Basis Dis."},{"key":"10.1016\/j.semcancer.2025.10.003_bib34","doi-asserted-by":"crossref","first-page":"93","DOI":"10.4103\/jrms.jrms_267_22","article-title":"The tangled web of dyslipidemia and cancer: is there any association?","volume":"27","author":"Neshat","year":"2022","journal-title":"J. Res Med Sci."},{"issue":"2","key":"10.1016\/j.semcancer.2025.10.003_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2020.188351","article-title":"Cholesterol and beyond - the role of the mevalonate pathway in cancer biology","volume":"1873","author":"Gobel","year":"2020","journal-title":"Biochim Biophys. Acta Rev. Cancer"},{"issue":"1","key":"10.1016\/j.semcancer.2025.10.003_bib36","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.cmet.2019.11.010","article-title":"Greasing the wheels of the cancer machine: the role of lipid metabolism in cancer","volume":"31","author":"Snaebjornsson","year":"2020","journal-title":"Cell Metab."},{"issue":"19","key":"10.1016\/j.semcancer.2025.10.003_bib37","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1056\/NEJMoa1201735","article-title":"Statin use and reduced cancer-related mortality","volume":"367","author":"Nielsen","year":"2012","journal-title":"N. Engl. J. Med"},{"issue":"4","key":"10.1016\/j.semcancer.2025.10.003_bib38","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1001\/jamaoncol.2022.7826","article-title":"Estimates and projections of the global economic cost of 29 cancers in 204 countries and territories from 2020 to 2050","volume":"9","author":"Chen","year":"2023","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.semcancer.2025.10.003_bib39","unstructured":"W.H. Organization, Global cancer burden growing amidst mounting need for services, 2024. \u3008https:\/\/www.who.int\/news\/item\/01-02-2024-global-cancer-burden-growing--amidst-mounting-need-for-services\u3009."},{"key":"10.1016\/j.semcancer.2025.10.003_bib40","unstructured":"I.A.f.R.o. Cancer, Global Cancer Observatory, 2025. \u3008https:\/\/gco.iarc.fr\/en\u3009."},{"issue":"2","key":"10.1016\/j.semcancer.2025.10.003_bib41","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/biostatistics\/kxx069","article-title":"Estimation of clinical trial success rates and related parameters","volume":"20","author":"Wong","year":"2019","journal-title":"Biostatistics"},{"key":"10.1016\/j.semcancer.2025.10.003_bib42","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.semcancer.2020.03.011","article-title":"Drug rechanneling: a novel paradigm for cancer treatment","volume":"68","author":"Kaushik","year":"2021","journal-title":"Semin Cancer Biol."},{"issue":"8","key":"10.1016\/j.semcancer.2025.10.003_bib43","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.semcancer.2025.10.003_bib44","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.drudis.2015.09.017","article-title":"Drug-repositioning opportunities for cancer therapy: novel molecular targets for known compounds","volume":"21","author":"Wurth","year":"2016","journal-title":"Drug Discov. Today"},{"issue":"5","key":"10.1016\/j.semcancer.2025.10.003_bib45","article-title":"Statins as anti-tumor agents: a paradigm for repurposed drugs","volume":"7","author":"Tripathi","year":"2024","journal-title":"Cancer Rep (Hoboken)"},{"issue":"38","key":"10.1016\/j.semcancer.2025.10.003_bib46","doi-asserted-by":"crossref","first-page":"62726","DOI":"10.18632\/oncotarget.10911","article-title":"Oncogenic regulation of tumor metabolic reprogramming","volume":"7","author":"Tarrado-Castellarnau","year":"2016","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.semcancer.2025.10.003_bib47","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/nrc.2016.76","article-title":"The interplay between cell signalling and the mevalonate pathway in cancer","volume":"16","author":"Mullen","year":"2016","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.semcancer.2025.10.003_bib48","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/nrd4204","article-title":"PI3K and cancer: lessons, challenges and opportunities","volume":"13","author":"Fruman","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"issue":"9","key":"10.1016\/j.semcancer.2025.10.003_bib49","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/s41580-018-0015-0","article-title":"The functions and regulation of the PTEN tumour suppressor: new modes and prospects","volume":"19","author":"Lee","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"2","key":"10.1016\/j.semcancer.2025.10.003_bib50","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/mutage\/geu045","article-title":"The expanding role of mTOR in cancer cell growth and proliferation","volume":"30","author":"Cargnello","year":"2015","journal-title":"Mutagenesis"},{"issue":"45","key":"10.1016\/j.semcancer.2025.10.003_bib51","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1038\/s41388-023-02836-x","article-title":"Dysregulation of cholesterol metabolism in cancer progression","volume":"42","author":"Liu","year":"2023","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.semcancer.2025.10.003_bib52","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ajpath.2010.11.005","article-title":"Role of cholesterol in the development and progression of breast cancer","volume":"178","author":"Llaverias","year":"2011","journal-title":"Am. J. Pathol."},{"issue":"3","key":"10.1016\/j.semcancer.2025.10.003_bib53","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.celrep.2012.08.011","article-title":"Anticancer activity of the cholesterol exporter ABCA1 gene","volume":"2","author":"Smith","year":"2012","journal-title":"Cell Rep."},{"issue":"2","key":"10.1016\/j.semcancer.2025.10.003_bib54","first-page":"219","article-title":"Cholesterol accumulation in prostate cancer: a classic observation from a modern perspective","volume":"1835","author":"Krycer","year":"2013","journal-title":"Biochim Biophys. Acta"},{"issue":"1-2","key":"10.1016\/j.semcancer.2025.10.003_bib55","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.cell.2011.12.017","article-title":"Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway","volume":"148","author":"Freed-Pastor","year":"2012","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.semcancer.2025.10.003_bib56","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1158\/0008-5472.CAN-15-2613","article-title":"The role of cholesterol in cancer","volume":"76","author":"Kuzu","year":"2016","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.semcancer.2025.10.003_bib57","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1194\/jlr.C066712","article-title":"Srebp2: a master regulator of sterol and fatty acid synthesis","volume":"57","author":"Madison","year":"2016","journal-title":"J. Lipid Res"},{"issue":"1","key":"10.1016\/j.semcancer.2025.10.003_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2020.188394","article-title":"Cholesterol metabolism: new functions and therapeutic approaches in cancer","volume":"1874","author":"Xu","year":"2020","journal-title":"Biochim Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.semcancer.2025.10.003_bib59","doi-asserted-by":"crossref","first-page":"466","DOI":"10.3389\/fphar.2016.00466","article-title":"Targeting the SR-B1 receptor as a gateway for cancer therapy and imaging","volume":"7","author":"Mooberry","year":"2016","journal-title":"Front Pharm."},{"issue":"11","key":"10.1016\/j.semcancer.2025.10.003_bib60","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0113789","article-title":"Akt inhibition promotes ABCA1-mediated cholesterol efflux to ApoA-I through suppressing mTORC1","volume":"9","author":"Dong","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.semcancer.2025.10.003_bib61","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.cmet.2015.03.002","article-title":"Uncoupling nuclear receptor LXR and cholesterol metabolism in cancer","volume":"21","author":"Bovenga","year":"2015","journal-title":"Cell Metab."},{"issue":"2","key":"10.1016\/j.semcancer.2025.10.003_bib62","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s42255-020-0174-0","article-title":"Cholesterol metabolism in cancer: mechanisms and therapeutic opportunities","volume":"2","author":"Huang","year":"2020","journal-title":"Nat. Metab."},{"issue":"1","key":"10.1016\/j.semcancer.2025.10.003_bib63","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1152\/physrev.2000.80.1.361","article-title":"Oxysterols: modulators of cholesterol metabolism and other processes","volume":"80","author":"Schroepfer","year":"2000","journal-title":"Physiol. Rev."},{"issue":"7","key":"10.1016\/j.semcancer.2025.10.003_bib64","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.tem.2017.03.002","article-title":"The role of oxysterols in human cancer","volume":"28","author":"Kloudova","year":"2017","journal-title":"Trends Endocrinol. Metab."},{"issue":"7","key":"10.1016\/j.semcancer.2025.10.003_bib65","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1002\/stem.1122","article-title":"Mevalonate metabolism regulates basal breast cancer stem cells and is a potential therapeutic target","volume":"30","author":"Ginestier","year":"2012","journal-title":"Stem Cells"},{"issue":"14","key":"10.1016\/j.semcancer.2025.10.003_bib66","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.4161\/cc.21092","article-title":"p53 and cancer stem cells: the mevalonate connexion","volume":"11","author":"Ginestier","year":"2012","journal-title":"Cell Cycle"},{"key":"10.1016\/j.semcancer.2025.10.003_bib67","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.622908","article-title":"Role of cholesterol and lipid rafts in cancer signaling: a promising therapeutic opportunity?","volume":"9","author":"Vona","year":"2021","journal-title":"Front Cell Dev. Biol."},{"key":"10.1016\/j.semcancer.2025.10.003_bib68","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jbior.2014.10.003","article-title":"Lipid rafts as major platforms for signaling regulation in cancer","volume":"57","author":"Mollinedo","year":"2015","journal-title":"Adv. Biol. Regul."},{"issue":"1","key":"10.1016\/j.semcancer.2025.10.003_bib69","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.13167","article-title":"Lipid raft involvement in signal transduction in cancer cell survival, cell death and metastasis","volume":"55","author":"Li","year":"2022","journal-title":"Cell Prolif."},{"issue":"10","key":"10.1016\/j.semcancer.2025.10.003_bib70","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/pros.20593","article-title":"Cholesterol level of lipid raft microdomains regulates apoptotic cell death in prostate cancer cells through EGFR-mediated akt and ERK signal transduction","volume":"67","author":"Oh","year":"2007","journal-title":"Prostate"},{"issue":"3","key":"10.1016\/j.semcancer.2025.10.003_bib71","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1158\/1541-7786.MCR-07-0117","article-title":"CXCL12\/CXCR4 transactivates HER2 in lipid rafts of prostate cancer cells and promotes growth of metastatic deposits in bone","volume":"6","author":"Chinni","year":"2008","journal-title":"Mol. Cancer Res"},{"key":"10.1016\/j.semcancer.2025.10.003_bib72","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ceb.2019.06.008","article-title":"The interplay of patched, smoothened and cholesterol in hedgehog signaling","volume":"61","author":"Hu","year":"2019","journal-title":"Curr. Opin. Cell Biol."},{"issue":"2","key":"10.1016\/j.semcancer.2025.10.003_bib73","first-page":"219","article-title":"The role of cholesterol metabolism in cancer","volume":"9","author":"Ding","year":"2019","journal-title":"Am. J. Cancer Res"},{"key":"10.1016\/j.semcancer.2025.10.003_bib74","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1038\/ncomms2221","article-title":"Cholesterol modulates cell signaling and protein networking by specifically interacting with PDZ domain-containing scaffold proteins","volume":"3","author":"Sheng","year":"2012","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.semcancer.2025.10.003_bib75","first-page":"342","article-title":"PI3K\/Akt\/mTOR inhibitors in breast cancer","volume":"12","author":"Lee","year":"2015","journal-title":"Cancer Biol. Med"},{"issue":"31","key":"10.1016\/j.semcancer.2025.10.003_bib76","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1200\/JCO.2014.59.0018","article-title":"Inhibition of the PI3K\/AKT\/mTOR pathway in solid tumors","volume":"34","author":"LoRusso","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.semcancer.2025.10.003_bib77","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/nrurol.2017.144","article-title":"WNT signalling in prostate cancer","volume":"14","author":"Murillo-Garzon","year":"2017","journal-title":"Nat. Rev. Urol."},{"issue":"9","key":"10.1016\/j.semcancer.2025.10.003_bib78","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1038\/s12276-023-01079-w","article-title":"Functional significance of cholesterol metabolism in cancer: from threat to treatment","volume":"55","author":"Xiao","year":"2023","journal-title":"Exp. Mol. Med"},{"issue":"6331","key":"10.1016\/j.semcancer.2025.10.003_bib79","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1126\/science.aag1417","article-title":"Lysosomal cholesterol activates mTORC1 via an SLC38A9-Niemann-Pick C1 signaling complex","volume":"355","author":"Castellano","year":"2017","journal-title":"Science"},{"issue":"16","key":"10.1016\/j.semcancer.2025.10.003_bib80","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1038\/onc.2016.363","article-title":"mTORC1 and mTORC2 in cancer and the tumor microenvironment","volume":"36","author":"Kim","year":"2017","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.semcancer.2025.10.003_bib81","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/s42255-022-00616-7","article-title":"Long non-coding RNA SNHG6 couples cholesterol sensing with mTORC1 activation in hepatocellular carcinoma","volume":"4","author":"Liu","year":"2022","journal-title":"Nat. Metab."},{"issue":"3","key":"10.1016\/j.semcancer.2025.10.003_bib82","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.celrep.2013.10.006","article-title":"27-Hydroxycholesterol promotes cell-autonomous, ER-positive breast cancer growth","volume":"5","author":"Wu","year":"2013","journal-title":"Cell Rep."},{"key":"10.1016\/j.semcancer.2025.10.003_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114621","article-title":"Our evolving understanding of how 27-hydroxycholesterol influences cancer","volume":"196","author":"Ma","year":"2022","journal-title":"Biochem Pharm."},{"issue":"1","key":"10.1016\/j.semcancer.2025.10.003_bib84","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1080\/15384101.2018.1558868","article-title":"CYP27A1 inhibits bladder cancer cells proliferation by regulating cholesterol homeostasis","volume":"18","author":"Liang","year":"2019","journal-title":"Cell Cycle"},{"issue":"29","key":"10.1016\/j.semcancer.2025.10.003_bib85","doi-asserted-by":"crossref","first-page":"46509","DOI":"10.18632\/oncotarget.10224","article-title":"Characterisation of the oxysterol metabolising enzyme pathway in mismatch repair proficient and deficient colorectal cancer","volume":"7","author":"Swan","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.semcancer.2025.10.003_bib86","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s12957-024-03504-4","article-title":"Association of CYP7B1 expression with the prognosis of endometrial cancer: a retrospective study","volume":"22","author":"Lu","year":"2024","journal-title":"World J. Surg. Oncol."},{"key":"10.1016\/j.semcancer.2025.10.003_bib87","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.molmet.2017.11.013","article-title":"Androgen receptor overexpression in prostate cancer in type 2 diabetes","volume":"8","author":"Lutz","year":"2018","journal-title":"Mol. Metab."},{"issue":"7","key":"10.1016\/j.semcancer.2025.10.003_bib88","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1530\/ERC-16-0533","article-title":"Impact of 27-hydroxylase (CYP27A1) and 27-hydroxycholesterol in breast cancer","volume":"24","author":"Kimbung","year":"2017","journal-title":"Endocr. Relat. Cancer"},{"issue":"10","key":"10.1016\/j.semcancer.2025.10.003_bib89","doi-asserted-by":"crossref","first-page":"4366","DOI":"10.1091\/mbc.e08-05-0449","article-title":"Spatiotemporal analysis of differential akt regulation in plasma membrane microdomains","volume":"19","author":"Gao","year":"2008","journal-title":"Mol. Biol. Cell"},{"issue":"1","key":"10.1016\/j.semcancer.2025.10.003_bib90","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1517\/14728222.2011.644788","article-title":"Targeting the PI3K signaling pathway in cancer therapy","volume":"16","author":"Bartholomeusz","year":"2012","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.semcancer.2025.10.003_bib91","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0065-230X(05)94002-5","article-title":"Activation of AKT kinases in cancer: implications for therapeutic targeting","volume":"94","author":"Bellacosa","year":"2005","journal-title":"Adv. Cancer Res"},{"issue":"4","key":"10.1016\/j.semcancer.2025.10.003_bib92","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.ajpath.2014.12.018","article-title":"Elevated levels of StAR-related lipid transfer protein 3 alter cholesterol balance and adhesiveness of breast cancer cells: potential mechanisms contributing to progression of HER2-positive breast cancers","volume":"185","author":"Vassilev","year":"2015","journal-title":"Am. J. Pathol."},{"issue":"13","key":"10.1016\/j.semcancer.2025.10.003_bib93","doi-asserted-by":"crossref","first-page":"5246","DOI":"10.1158\/0008-5472.CAN-07-6161","article-title":"Mitochondrial cholesterol contributes to chemotherapy resistance in hepatocellular carcinoma","volume":"68","author":"Montero","year":"2008","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.semcancer.2025.10.003_bib94","doi-asserted-by":"crossref","first-page":"5103","DOI":"10.1038\/s41467-021-25354-4","article-title":"Dysregulated cholesterol homeostasis results in resistance to ferroptosis increasing tumorigenicity and metastasis in cancer","volume":"12","author":"Liu","year":"2021","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.semcancer.2025.10.003_bib95","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1194\/jlr.M069906","article-title":"Oxysterol binding protein-related protein 8 mediates the cytotoxicity of 25-hydroxycholesterol","volume":"57","author":"Li","year":"2016","journal-title":"J. Lipid Res"},{"issue":"1","key":"10.1016\/j.semcancer.2025.10.003_bib96","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2013.524","article-title":"Induction of apoptosis and necroptosis by 24(S)-hydroxycholesterol is dependent on activity of acyl-CoA:cholesterol acyltransferase 1","volume":"5","author":"Yamanaka","year":"2014","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.semcancer.2025.10.003_bib97","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41392-020-0134-x","article-title":"Molecular principles of metastasis: a hallmark of cancer revisited","volume":"5","author":"Fares","year":"2020","journal-title":"Signal Transduct. Target Ther."},{"issue":"4","key":"10.1016\/j.semcancer.2025.10.003_bib98","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/PPO.0000000000000138","article-title":"The contribution of angiogenesis to the process of metastasis","volume":"21","author":"Bielenberg","year":"2015","journal-title":"Cancer J."},{"key":"10.1016\/j.semcancer.2025.10.003_bib99","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.896099","article-title":"Insights into the role of matrix metalloproteinases in cancer and its various therapeutic aspects: a review","volume":"9","author":"Mustafa","year":"2022","journal-title":"Front Mol. Biosci."},{"issue":"6","key":"10.1016\/j.semcancer.2025.10.003_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100773","article-title":"Epithelial-Mesenchymal transition in cancer: a historical overview","volume":"13","author":"Ribatti","year":"2020","journal-title":"Transl. Oncol."},{"issue":"2","key":"10.1016\/j.semcancer.2025.10.003_bib101","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22020798","article-title":"Lipid raft association stabilizes VEGF receptor 2 in endothelial cells","volume":"22","author":"Zabroski","year":"2021","journal-title":"Int J. Mol. Sci."},{"issue":"7452","key":"10.1016\/j.semcancer.2025.10.003_bib102","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nature12166","article-title":"Control of angiogenesis by AIBP-mediated cholesterol efflux","volume":"498","author":"Fang","year":"2013","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.semcancer.2025.10.003_bib103","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s12967-019-1910-7","article-title":"AIBP and APOA-I synergistically inhibit intestinal tumor growth and metastasis by promoting cholesterol efflux","volume":"17","author":"Zhang","year":"2019","journal-title":"J. Transl. Med"},{"issue":"41","key":"10.1016\/j.semcancer.2025.10.003_bib104","doi-asserted-by":"crossref","first-page":"E6219","DOI":"10.1073\/pnas.1613332113","article-title":"24-Hydroxycholesterol participates in pancreatic neuroendocrine tumor development","volume":"113","author":"Soncini","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.semcancer.2025.10.003_bib105","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.toxlet.2016.11.006","article-title":"The ROS-mediated activation of STAT-3\/VEGF signaling is involved in the 27-hydroxycholesterol-induced angiogenesis in human breast cancer cells","volume":"264","author":"Zhu","year":"2016","journal-title":"Toxicol. Lett."},{"issue":"1","key":"10.1016\/j.semcancer.2025.10.003_bib106","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1158\/0008-5472.CAN-20-2199","article-title":"Rafting down the metastatic cascade: the role of lipid rafts in cancer metastasis, cell death, and clinical outcomes","volume":"81","author":"Greenlee","year":"2021","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.semcancer.2025.10.003_bib107","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1091\/mbc.e08-09-0898","article-title":"Specific activation of mitogen-activated protein kinase by transforming growth factor-beta receptors in lipid rafts is required for epithelial cell plasticity","volume":"20","author":"Zuo","year":"2009","journal-title":"Mol. Biol. Cell"},{"issue":"26","key":"10.1016\/j.semcancer.2025.10.003_bib108","doi-asserted-by":"crossref","first-page":"18145","DOI":"10.1074\/jbc.M512566200","article-title":"Metastatic potential of mouse lewis lung cancer cells is regulated via ganglioside GM1 by modulating the matrix metalloprotease-9 localization in lipid rafts","volume":"281","author":"Zhang","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.semcancer.2025.10.003_bib109","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/s41388-018-0448-0","article-title":"A novel cross-talk between CXCR4 and PI4KIIIalpha in prostate cancer cells","volume":"38","author":"Sbrissa","year":"2019","journal-title":"Oncogene"},{"issue":"22","key":"10.1016\/j.semcancer.2025.10.003_bib110","doi-asserted-by":"crossref","first-page":"8594","DOI":"10.1158\/0008-5472.CAN-09-2305","article-title":"Lipid rafts and caveolin-1 are required for invadopodia formation and extracellular matrix degradation by human breast cancer cells","volume":"69","author":"Yamaguchi","year":"2009","journal-title":"Cancer Res"},{"issue":"13","key":"10.1016\/j.semcancer.2025.10.003_bib111","doi-asserted-by":"crossref","first-page":"4527","DOI":"10.1158\/0008-5472.CAN-10-4376","article-title":"Cancer cell-associated MT1-MMP promotes blood vessel invasion and distant metastasis in triple-negative mammary tumors","volume":"71","author":"Perentes","year":"2011","journal-title":"Cancer Res"},{"issue":"40","key":"10.1016\/j.semcancer.2025.10.003_bib112","doi-asserted-by":"crossref","first-page":"37491","DOI":"10.1074\/jbc.M104094200","article-title":"Membrane type 1-matrix metalloproteinase is activated during migration of human endothelial cells and modulates endothelial motility and matrix remodeling","volume":"276","author":"Galvez","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.semcancer.2025.10.003_bib113","doi-asserted-by":"crossref","first-page":"a005074","DOI":"10.1101\/cshperspect.a005074","article-title":"Integrins in cell migration","volume":"3","author":"Huttenlocher","year":"2011","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"Pt 5","key":"10.1016\/j.semcancer.2025.10.003_bib114","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1242\/jcs.115.5.963","article-title":"The involvement of lipid rafts in the regulation of integrin function","volume":"115","author":"Leitinger","year":"2002","journal-title":"J. Cell Sci."},{"issue":"9","key":"10.1016\/j.semcancer.2025.10.003_bib115","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.bbalip.2015.06.001","article-title":"Disruption of the mevalonate pathway induces dNTP depletion and DNA damage","volume":"1851","author":"Martin Sanchez","year":"2015","journal-title":"Biochim Biophys. Acta"},{"issue":"61","key":"10.1016\/j.semcancer.2025.10.003_bib116","doi-asserted-by":"crossref","first-page":"104136","DOI":"10.18632\/oncotarget.22024","article-title":"Cholesterol overload in the liver aggravates oxidative stress-mediated DNA damage and accelerates hepatocarcinogenesis","volume":"8","author":"Enriquez-Cortina","year":"2017","journal-title":"Oncotarget"},{"issue":"23","key":"10.1016\/j.semcancer.2025.10.003_bib117","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1080\/15384101.2019.1676581","article-title":"Cholesterol depletion sensitizes gallbladder cancer to cisplatin by impairing DNA damage response","volume":"18","author":"Zhang","year":"2019","journal-title":"Cell Cycle"},{"issue":"1","key":"10.1016\/j.semcancer.2025.10.003_bib118","doi-asserted-by":"crossref","first-page":"4490","DOI":"10.1038\/s41467-018-06931-6","article-title":"Dietary cholesterol promotes steatohepatitis related hepatocellular carcinoma through dysregulated metabolism and calcium signaling","volume":"9","author":"Liang","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.semcancer.2025.10.003_bib119","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.bcp.2016.02.017","article-title":"Dietary cholesterol promotes AOM-induced colorectal cancer through activating the NLRP3 inflammasome","volume":"105","author":"Du","year":"2016","journal-title":"Biochem Pharm."},{"issue":"12","key":"10.1016\/j.semcancer.2025.10.003_bib120","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1016\/j.yexcr.2013.03.025","article-title":"On the role of 25-hydroxycholesterol synthesis by glioblastoma cell lines. Implications for chemotactic monocyte recruitment","volume":"319","author":"Eibinger","year":"2013","journal-title":"Exp. Cell Res"},{"issue":"1","key":"10.1016\/j.semcancer.2025.10.003_bib121","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/2045-824X-4-14","article-title":"Myeloid cells in tumor inflammation","volume":"4","author":"Schmid","year":"2012","journal-title":"Vasc. Cell"},{"issue":"12","key":"10.1016\/j.semcancer.2025.10.003_bib122","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/j.cmet.2022.10.010","article-title":"Cancer cell-intrinsic XBP1 drives immunosuppressive reprogramming of intratumoral myeloid cells by promoting cholesterol production","volume":"34","author":"Yang","year":"2022","journal-title":"Cell Metab."},{"issue":"7","key":"10.1016\/j.semcancer.2025.10.003_bib123","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/s41423-022-00872-3","article-title":"Aberrant cholesterol metabolic signaling impairs antitumor immunosurveillance through natural killer t cell dysfunction in obese liver","volume":"19","author":"Tang","year":"2022","journal-title":"Cell Mol. Immunol."},{"issue":"1","key":"10.1016\/j.semcancer.2025.10.003_bib124","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.cmet.2019.04.002","article-title":"Cholesterol induces CD8(+) t cell exhaustion in the tumor microenvironment","volume":"30","author":"Ma","year":"2019","journal-title":"Cell Metab."},{"issue":"5","key":"10.1016\/j.semcancer.2025.10.003_bib125","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1002\/ijc.30526","article-title":"Effects of statins on cancer mortality and progression: a systematic review and meta-analysis of 95 cohorts including 1,111,407 individuals","volume":"140","author":"Mei","year":"2017","journal-title":"Int J. Cancer"},{"issue":"1","key":"10.1016\/j.semcancer.2025.10.003_bib126","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s12944-023-01955-4","article-title":"The association of statin therapy and cancer: a meta-analysis","volume":"22","author":"Chen","year":"2023","journal-title":"Lipids Health Dis."},{"issue":"1","key":"10.1016\/j.semcancer.2025.10.003_bib127","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jama.295.1.74","article-title":"Statins and cancer risk: a meta-analysis","volume":"295","author":"Dale","year":"2006","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.semcancer.2025.10.003_bib128","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jacc.2007.02.073","article-title":"Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials","volume":"50","author":"Alsheikh-Ali","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"10.1016\/j.semcancer.2025.10.003_bib129","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.18632\/oncotarget.6304","article-title":"Simvastatin-induced breast cancer cell death and deactivation of PI3K\/Akt and MAPK\/ERK signalling are reversed by metabolic products of the mevalonate pathway","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.semcancer.2025.10.003_bib130","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.cellsig.2009.12.010","article-title":"Simvastatin induces derepression of PTEN expression via NFkappaB to inhibit breast cancer cell growth","volume":"22","author":"Ghosh-Choudhury","year":"2010","journal-title":"Cell Signal"},{"key":"10.1016\/j.semcancer.2025.10.003_bib131","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12967-015-0486-0","article-title":"Statin-induced anti-proliferative effects via cyclin D1 and p27 in a window-of-opportunity breast cancer trial","volume":"13","author":"Feldt","year":"2015","journal-title":"J. Transl. Med"},{"issue":"7015","key":"10.1016\/j.semcancer.2025.10.003_bib132","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature03094","article-title":"G1 cell-cycle control and cancer","volume":"432","author":"Massague","year":"2004","journal-title":"Nature"},{"issue":"17","key":"10.1016\/j.semcancer.2025.10.003_bib133","doi-asserted-by":"crossref","first-page":"8022","DOI":"10.1073\/pnas.91.17.8022","article-title":"Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle","volume":"91","author":"Musgrove","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.semcancer.2025.10.003_bib134","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nrc2347","article-title":"The cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy","volume":"8","author":"Chu","year":"2008","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.semcancer.2025.10.003_bib135","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s10549-009-0507-x","article-title":"Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer","volume":"119","author":"Garwood","year":"2010","journal-title":"Breast Cancer Res Treat."},{"issue":"4","key":"10.1016\/j.semcancer.2025.10.003_bib136","doi-asserted-by":"crossref","first-page":"935","DOI":"10.3892\/ijo.2011.1273","article-title":"Simvastatin inhibits cancer cell growth by inducing apoptosis correlated to activation of bax and down-regulation of BCL-2 gene expression","volume":"40","author":"Spampanato","year":"2012","journal-title":"Int J. Oncol."},{"issue":"9","key":"10.1016\/j.semcancer.2025.10.003_bib137","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/sj.onc.1210220","article-title":"The Bcl-2 apoptotic switch in cancer development and therapy","volume":"26","author":"Adams","year":"2007","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.semcancer.2025.10.003_bib138","doi-asserted-by":"crossref","first-page":"256","DOI":"10.4274\/balkanmedj.2017.0604","article-title":"Evaluation of the cytotoxic and autophagic effects of atorvastatin on MCF-7 breast cancer cells","volume":"35","author":"Alarcon Martinez","year":"2018","journal-title":"Balk. Med J."},{"issue":"6","key":"10.1016\/j.semcancer.2025.10.003_bib139","article-title":"Novel effects of statins on cancer via autophagy","volume":"15","author":"Mengual","year":"2022","journal-title":"Pharm. (Basel)"},{"issue":"3","key":"10.1016\/j.semcancer.2025.10.003_bib140","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/s41418-019-0474-7","article-title":"Autophagy in cancer: moving from understanding mechanism to improving therapy responses in patients","volume":"27","author":"Levy","year":"2020","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.semcancer.2025.10.003_bib141","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/B978-0-12-407173-5.00003-0","article-title":"Autophagy: cancer's friend or foe?","volume":"118","author":"Bhutia","year":"2013","journal-title":"Adv. Cancer Res"},{"issue":"11","key":"10.1016\/j.semcancer.2025.10.003_bib142","doi-asserted-by":"crossref","first-page":"17833","DOI":"10.18632\/oncotarget.14868","article-title":"Mevastatin blockade of autolysosome maturation stimulates LBH589-induced cell death in triple-negative breast cancer cells","volume":"8","author":"Lin","year":"2017","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.semcancer.2025.10.003_bib143","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1093\/ehjcvp\/pvad057","article-title":"Post-diagnostic statin use and its association with cancer recurrence and mortality in breast cancer patients: a systematic review and meta-analysis","volume":"9","author":"Jaiswal","year":"2023","journal-title":"Eur. Heart J. Cardiovasc Pharm."},{"issue":"4","key":"10.1016\/j.semcancer.2025.10.003_bib144","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.4143\/crt.2020.1024","article-title":"Combination of simvastatin and FAC improves response to neoadjuvant chemotherapy in locally advanced breast cancer","volume":"53","author":"Yulian","year":"2021","journal-title":"Cancer Res Treat."},{"issue":"2","key":"10.1016\/j.semcancer.2025.10.003_bib145","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1124\/jpet.110.174870","article-title":"Anticancer efficacy of simvastatin on prostate cancer cells and tumor xenografts is associated with inhibition of akt and reduced prostate-specific antigen expression","volume":"336","author":"Kochuparambil","year":"2011","journal-title":"J. Pharm. Exp. Ther."},{"issue":"1","key":"10.1016\/j.semcancer.2025.10.003_bib146","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1158\/1055-9965.EPI-07-0531","article-title":"Statin induces apoptosis and cell growth arrest in prostate cancer cells","volume":"17","author":"Hoque","year":"2008","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"issue":"4","key":"10.1016\/j.semcancer.2025.10.003_bib147","first-page":"542","article-title":"Statins and prostate cancer: role of cholesterol inhibition vs. Prevention of small GTP-binding proteins","volume":"1","author":"Roy","year":"2011","journal-title":"Am. J. Cancer Res"},{"issue":"34","key":"10.1016\/j.semcancer.2025.10.003_bib148","doi-asserted-by":"crossref","first-page":"4735","DOI":"10.1038\/s41388-018-0318-9","article-title":"COX-2 mediates pro-tumorigenic effects of PKCepsilon in prostate cancer","volume":"37","author":"Garg","year":"2018","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.semcancer.2025.10.003_bib149","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1158\/1940-6207.CAPR-09-0059","article-title":"Atorvastatin and celecoxib in combination inhibits the progression of androgen-dependent LNCaP xenograft prostate tumors to androgen independence","volume":"3","author":"Zheng","year":"2010","journal-title":"Cancer Prev Res (Phila)"},{"issue":"1","key":"10.1016\/j.semcancer.2025.10.003_bib150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00345-004-0473-1","article-title":"Mechanisms of the development of androgen independence in prostate cancer","volume":"23","author":"So","year":"2005","journal-title":"World J. Urol."},{"issue":"4","key":"10.1016\/j.semcancer.2025.10.003_bib151","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S0959-8049(96)00510-2","article-title":"Evolving strategies of cytotoxic chemotherapy for advanced prostate cancer","volume":"33","author":"Raghavan","year":"1997","journal-title":"Eur. J. Cancer"},{"issue":"37","key":"10.1016\/j.semcancer.2025.10.003_bib152","doi-asserted-by":"crossref","first-page":"14328","DOI":"10.1074\/jbc.RA118.004442","article-title":"Inhibition of cholesterol biosynthesis overcomes enzalutamide resistance in castration-resistant prostate cancer (CRPC)","volume":"293","author":"Kong","year":"2018","journal-title":"J. Biol. Chem."},{"issue":"10","key":"10.1016\/j.semcancer.2025.10.003_bib153","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1038\/bjc.2012.138","article-title":"The differential effects of statins on the metastatic behaviour of prostate cancer","volume":"106","author":"Brown","year":"2012","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.semcancer.2025.10.003_bib154","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41391-020-0221-7","article-title":"A pilot window-of-opportunity study of preoperative fluvastatin in localized prostate cancer","volume":"23","author":"Longo","year":"2020","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"6","key":"10.1016\/j.semcancer.2025.10.003_bib155","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.eururo.2018.06.037","article-title":"Atorvastatin versus placebo for prostate cancer before radical Prostatectomy-A randomized, Double-blind, Placebo-controlled clinical trial","volume":"74","author":"Murtola","year":"2018","journal-title":"Eur. Urol."},{"key":"10.1016\/j.semcancer.2025.10.003_bib156","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2025.101132","article-title":"The impact of atorvastatin on intraprostatic biomarkers - prognostic value of 3LS-score - Follow-up of ESTO1-Trial","volume":"61","author":"Lehtonen","year":"2025","journal-title":"Neoplasia"},{"issue":"7","key":"10.1016\/j.semcancer.2025.10.003_bib157","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/COC.0000000000001012","article-title":"Association between statin exposure and incidence and prognosis of prostate cancer: a Meta-analysis based on observational studies","volume":"46","author":"Cao","year":"2023","journal-title":"Am. J. Clin. Oncol."},{"issue":"14","key":"10.1016\/j.semcancer.2025.10.003_bib158","doi-asserted-by":"crossref","first-page":"4640","DOI":"10.1158\/1078-0432.CCR-07-5232","article-title":"Statin-dependent suppression of the akt\/mammalian target of rapamycin signaling cascade and programmed cell death 4 up-regulation in renal cell carcinoma","volume":"14","author":"Woodard","year":"2008","journal-title":"Clin. Cancer Res"},{"issue":"3","key":"10.1016\/j.semcancer.2025.10.003_bib159","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/bcp.12210","article-title":"Statin use and risk of kidney cancer: a meta-analysis of observational studies and randomized trials","volume":"77","author":"Zhang","year":"2014","journal-title":"Br. J. Clin. Pharm."},{"key":"10.1016\/j.semcancer.2025.10.003_bib160","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ctrv.2016.11.009","article-title":"Statin use and kidney cancer survival outcomes: a systematic review and meta-analysis","volume":"52","author":"Nayan","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.semcancer.2025.10.003_bib161","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1132177","article-title":"Influence of statin use on prognosis of patients with renal cell cancer: a meta-analysis","volume":"13","author":"Liang","year":"2023","journal-title":"Front Oncol."},{"key":"10.1016\/j.semcancer.2025.10.003_bib162","doi-asserted-by":"crossref","first-page":"1048484","DOI":"10.3389\/fphar.2022.1048484","article-title":"Advances in ovarian cancer treatment using a combination of statins with other drugs","volume":"13","author":"Xia","year":"2022","journal-title":"Front Pharm."},{"issue":"2","key":"10.1016\/j.semcancer.2025.10.003_bib163","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3892\/ol.2022.13648","article-title":"Statin use improves the prognosis of ovarian cancer: an updated and comprehensive meta-analysis","volume":"25","author":"Wang","year":"2023","journal-title":"Oncol. Lett."},{"issue":"3","key":"10.1016\/j.semcancer.2025.10.003_bib164","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.ygyno.2014.04.007","article-title":"Effect of statin on risk of gynecologic cancers: a meta-analysis of observational studies and randomized controlled trials","volume":"133","author":"Liu","year":"2014","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.semcancer.2025.10.003_bib165","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1186\/s12885-019-5954-0","article-title":"Statin use and the risk of ovarian and endometrial cancers: a meta-analysis","volume":"19","author":"Wang","year":"2019","journal-title":"BMC Cancer"},{"issue":"47","key":"10.1016\/j.semcancer.2025.10.003_bib166","article-title":"The association between statin use and endometrial cancer survival outcome: a meta-analysis","volume":"97","author":"Li","year":"2018","journal-title":"Med. (Baltim. )"},{"issue":"10","key":"10.1016\/j.semcancer.2025.10.003_bib167","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1097\/01.LAB.0000032411.41603.C2","article-title":"Impact of insulin-like growth factor receptor-I function on angiogenesis, growth, and metastasis of colon cancer","volume":"82","author":"Reinmuth","year":"2002","journal-title":"Lab Invest"},{"issue":"1","key":"10.1016\/j.semcancer.2025.10.003_bib168","doi-asserted-by":"crossref","first-page":"250","DOI":"10.3892\/ol.2016.4569","article-title":"Statin induces apoptosis of human colon cancer cells and downregulation of insulin-like growth factor 1 receptor via proapoptotic ERK activation","volume":"12","author":"Jang","year":"2016","journal-title":"Oncol. Lett."},{"issue":"8","key":"10.1016\/j.semcancer.2025.10.003_bib169","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1016\/j.bbagen.2013.04.011","article-title":"Simvastatin induced HCT116 colorectal cancer cell apoptosis through p38MAPK-p53-survivin signaling cascade","volume":"1830","author":"Chang","year":"2013","journal-title":"Biochim Biophys. Acta"},{"issue":"10","key":"10.1016\/j.semcancer.2025.10.003_bib170","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a026831","article-title":"HDACs and HDAC inhibitors in cancer development and therapy","volume":"6","author":"Li","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med"},{"issue":"11","key":"10.1016\/j.semcancer.2025.10.003_bib171","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1002\/ijc.28672","article-title":"Statins inhibit tumor progression via an enhancer of zeste homolog 2-mediated epigenetic alteration in colorectal cancer","volume":"135","author":"Ishikawa","year":"2014","journal-title":"Int J. Cancer"},{"issue":"11","key":"10.1016\/j.semcancer.2025.10.003_bib172","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1136\/gut.2011.237495","article-title":"Statins augment the chemosensitivity of colorectal cancer cells inducing epigenetic reprogramming and reducing colorectal cancer cell 'stemness' via the bone morphogenetic protein pathway","volume":"60","author":"Kodach","year":"2011","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.semcancer.2025.10.003_bib173","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1053\/j.gastro.2010.12.035","article-title":"5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer","volume":"140","author":"Jover","year":"2011","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.semcancer.2025.10.003_bib174","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.bbrc.2014.02.078","article-title":"HMG-CoA reductase regulates CCL17-induced colon cancer cell migration via geranylgeranylation and RhoA activation","volume":"446","author":"Al-Haidari","year":"2014","journal-title":"Biochem Biophys. Res Commun."},{"issue":"11","key":"10.1016\/j.semcancer.2025.10.003_bib175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0112201","article-title":"Statin use is not associated with improved progression free survival in cetuximab treated KRAS mutant metastatic colorectal cancer patients: results from the CAIRO2 study","volume":"9","author":"Krens","year":"2014","journal-title":"PLoS One"},{"issue":"13-14","key":"10.1016\/j.semcancer.2025.10.003_bib176","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.drudis.2010.05.012","article-title":"Therapeutic modulation of k-ras signaling in colorectal cancer","volume":"15","author":"Krens","year":"2010","journal-title":"Drug Discov. Today"},{"issue":"7","key":"10.1016\/j.semcancer.2025.10.003_bib177","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.ctrv.2004.06.010","article-title":"Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer","volume":"30","author":"Graaf","year":"2004","journal-title":"Cancer Treat. Rev."},{"issue":"10","key":"10.1016\/j.semcancer.2025.10.003_bib178","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1038\/bjc.2015.371","article-title":"A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI\/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer","volume":"113","author":"Lim","year":"2015","journal-title":"Br. J. Cancer"},{"issue":"6","key":"10.1016\/j.semcancer.2025.10.003_bib179","doi-asserted-by":"crossref","first-page":"3305","DOI":"10.1002\/cam4.2151","article-title":"Statin uses and mortality in colorectal cancer patients: an updated systematic review and meta-analysis","volume":"8","author":"Li","year":"2019","journal-title":"Cancer Med"},{"issue":"2","key":"10.1016\/j.semcancer.2025.10.003_bib180","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2012.10.005","article-title":"Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis","volume":"144","author":"Singh","year":"2013","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.semcancer.2025.10.003_bib181","first-page":"76","article-title":"Caspase-7 is activated during lovastatin-induced apoptosis of the prostate cancer cell line LNCaP","volume":"58","author":"Marcelli","year":"1998","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.semcancer.2025.10.003_bib182","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1086\/597039","article-title":"Antimicrobial and immunomodulatory attributes of statins: relevance in solid-organ transplant recipients","volume":"48","author":"Sun","year":"2009","journal-title":"Clin. Infect. Dis."},{"issue":"6","key":"10.1016\/j.semcancer.2025.10.003_bib183","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.cgh.2012.12.036","article-title":"Statins are associated with reduced risk of esophageal cancer, particularly in patients with barrett's esophagus: a systematic review and meta-analysis","volume":"11","author":"Singh","year":"2013","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.semcancer.2025.10.003_bib184","doi-asserted-by":"crossref","first-page":"243","DOI":"10.5603\/CJ.a2022.0014","article-title":"Statins and the risk of pancreatic cancer: a systematic review and meta-analysis of 2,797,186 patients","volume":"31","author":"Karbowska","year":"2024","journal-title":"Cardiol. J."},{"issue":"23","key":"10.1016\/j.semcancer.2025.10.003_bib185","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11237180","article-title":"Statins and the risk of gastric cancer: a systematic review and Meta-Analysis","volume":"11","author":"Su","year":"2022","journal-title":"J. Clin. Med"},{"key":"10.1016\/j.semcancer.2025.10.003_bib186","doi-asserted-by":"crossref","first-page":"4938539","DOI":"10.1155\/2022\/4938539","article-title":"Statins are associated with improved survival of patients with gastric cancer: a systematic review and Meta-Analysis","author":"Yuan","year":"2022","journal-title":"Int J. Clin. Pr. 2022"},{"issue":"3","key":"10.1016\/j.semcancer.2025.10.003_bib187","doi-asserted-by":"crossref","first-page":"240","DOI":"10.4149\/neo_2013_032","article-title":"Simvastatin prevents proliferation and bone metastases of lung adenocarcinoma in vitro and in vivo","volume":"60","author":"Liu","year":"2013","journal-title":"Neoplasma"},{"issue":"7","key":"10.1016\/j.semcancer.2025.10.003_bib188","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.ejca.2010.02.024","article-title":"CD44, a therapeutic target for metastasising tumours","volume":"46","author":"Orian-Rousseau","year":"2010","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.semcancer.2025.10.003_bib189","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.cell.2008.06.006","article-title":"Growth-inhibitory and tumor- suppressive functions of p53 depend on its repression of CD44 expression","volume":"134","author":"Godar","year":"2008","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.semcancer.2025.10.003_bib190","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1002\/jcp.22895","article-title":"Inhibition of lung cancer growth: ATP citrate lyase knockdown and statin treatment leads to dual blockade of mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3-kinase (PI3K)\/AKT pathways","volume":"227","author":"Hanai","year":"2012","journal-title":"J. Cell Physiol."},{"key":"10.1016\/j.semcancer.2025.10.003_bib191","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2147\/DDDT.S187690","article-title":"Statin use and prognosis of lung cancer: a systematic review and meta-analysis of observational studies and randomized controlled trials","volume":"13","author":"Xia","year":"2019","journal-title":"Drug Des. Dev. Ther."},{"issue":"1","key":"10.1016\/j.semcancer.2025.10.003_bib192","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.pharep.2014.01.002","article-title":"Fluvastatin inhibits growth and alters the malignant phenotype of the C6 glioma cell line","volume":"66","author":"Slawinska-Brych","year":"2014","journal-title":"Pharm. Rep."},{"issue":"3","key":"10.1016\/j.semcancer.2025.10.003_bib193","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s40265-021-01668-x","article-title":"Statins and gliomas: a systematic review of the preclinical studies and Meta-Analysis of the clinical literature","volume":"82","author":"Rendon","year":"2022","journal-title":"Drugs"},{"issue":"9","key":"10.1016\/j.semcancer.2025.10.003_bib194","article-title":"Whether statin use improves the survival of patients with glioblastoma?: a meta-analysis","volume":"99","author":"Xie","year":"2020","journal-title":"Med. (Baltim. )"},{"issue":"11","key":"10.1016\/j.semcancer.2025.10.003_bib195","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s10654-019-00565-8","article-title":"Statin use, hyperlipidemia, and risk of glioma","volume":"34","author":"Cote","year":"2019","journal-title":"Eur. J. Epidemiol."},{"issue":"3","key":"10.1016\/j.semcancer.2025.10.003_bib196","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3892\/ijo.2017.4071","article-title":"Additive antitumor effects of celecoxib and simvastatin on head and neck squamous cell carcinoma in vitro","volume":"51","author":"Gehrke","year":"2017","journal-title":"Int J. Oncol."},{"issue":"3","key":"10.1016\/j.semcancer.2025.10.003_bib197","doi-asserted-by":"crossref","DOI":"10.1186\/bcr1680","article-title":"Stat3 is tyrosine-phosphorylated through the interleukin-6\/glycoprotein 130\/Janus kinase pathway in breast cancer","volume":"9","author":"Berishaj","year":"2007","journal-title":"Breast Cancer Res"},{"issue":"2","key":"10.1016\/j.semcancer.2025.10.003_bib198","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ccr.2009.01.002","article-title":"gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis","volume":"15","author":"Bollrath","year":"2009","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.semcancer.2025.10.003_bib199","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1164\/ajrccm.162.5.2002108","article-title":"Interleukin-8 messenger ribonucleic acid expression correlates with tumor progression, tumor angiogenesis, patient survival, and timing of relapse in non-small-cell lung cancer","volume":"162","author":"Yuan","year":"2000","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"12","key":"10.1016\/j.semcancer.2025.10.003_bib200","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15123093","article-title":"Statin medication improves Five-Year survival rates in patients with head and neck cancer: a retrospective Case-Control study of about 100,000 patients","volume":"15","author":"Wuster","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.semcancer.2025.10.003_bib201","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/CMR.0000000000001001","article-title":"The impact of statins on melanoma survival: a systematic review and meta-analysis","volume":"34","author":"McKechnie","year":"2024","journal-title":"Melanoma Res"},{"key":"10.1016\/j.semcancer.2025.10.003_bib202","doi-asserted-by":"crossref","first-page":"1234713","DOI":"10.3389\/fonc.2023.1234713","article-title":"The effects of statins in patients with advanced-stage cancers - a systematic review and meta-analysis","volume":"13","author":"Zhou","year":"2023","journal-title":"Front Oncol."},{"issue":"15","key":"10.1016\/j.semcancer.2025.10.003_bib203","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15153948","article-title":"Statins in cancer prevention and therapy","volume":"15","author":"Ricco","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.semcancer.2025.10.003_bib204","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s10637-020-00992-5","article-title":"Atorvastatin in combination with radiotherapy and temozolomide for glioblastoma: a prospective phase II study","volume":"39","author":"Altwairgi","year":"2021","journal-title":"Invest N. Drugs"},{"key":"10.1016\/j.semcancer.2025.10.003_bib205","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.oraloncology.2019.01.019","article-title":"Statin use associated with improved overall and cancer specific survival in patients with head and neck cancer","volume":"90","author":"Gupta","year":"2019","journal-title":"Oral. Oncol."},{"issue":"10","key":"10.1016\/j.semcancer.2025.10.003_bib206","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1002\/ijc.33441","article-title":"Statin use and head and neck squamous cell carcinoma outcomes","volume":"148","author":"Getz","year":"2021","journal-title":"Int J. Cancer"},{"issue":"8","key":"10.1016\/j.semcancer.2025.10.003_bib207","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1002\/hed.25152","article-title":"Effect of statin use on oncologic outcomes in head and neck squamous cell carcinoma","volume":"40","author":"Lebo","year":"2018","journal-title":"Head. Neck"},{"issue":"4","key":"10.1016\/j.semcancer.2025.10.003_bib208","doi-asserted-by":"crossref","DOI":"10.1177\/2473974X211065715","article-title":"Repurposing statin drugs to decrease toxicity and improve survival outcomes in head and neck cancer","volume":"5","author":"Bourguillon","year":"2021","journal-title":"OTO Open"},{"key":"10.1016\/j.semcancer.2025.10.003_bib209","first-page":"6243","article-title":"Simvastatin potentiates doxorubicin activity against MCF-7 breast cancer cells","author":"Buranrat","year":"2017","journal-title":"Oncol. Lett. 14(5"},{"issue":"8","key":"10.1016\/j.semcancer.2025.10.003_bib210","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jtho.2023.04.005","article-title":"Statin use during concurrent chemoradiotherapy with improved survival outcomes in esophageal squamous cell carcinoma: a propensity Score-Matched nationwide cohort study","volume":"18","author":"Chen","year":"2023","journal-title":"J. Thorac. Oncol."},{"issue":"9","key":"10.1016\/j.semcancer.2025.10.003_bib211","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1002\/1878-0261.12535","article-title":"Mevalonate pathway activity as a determinant of radiation sensitivity in head and neck cancer","volume":"13","author":"Ricco","year":"2019","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.semcancer.2025.10.003_bib212","doi-asserted-by":"crossref","first-page":"1324140","DOI":"10.3389\/fphar.2024.1324140","article-title":"Statin therapy: a potential adjuvant to immunotherapies in hepatocellular carcinoma","volume":"15","author":"Wang","year":"2024","journal-title":"Front Pharm."},{"key":"10.1016\/j.semcancer.2025.10.003_bib213","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejca.2020.10.031","article-title":"High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients","volume":"144","author":"Cantini","year":"2021","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.semcancer.2025.10.003_bib214","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005940","article-title":"Statin drugs enhance responses to immune checkpoint blockade in head and neck cancer models","volume":"11","author":"Kansal","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.semcancer.2025.10.003_bib215","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ejca.2022.04.035","article-title":"Statin use improves the efficacy of nivolumab in patients with advanced renal cell carcinoma","volume":"172","author":"Santoni","year":"2022","journal-title":"Eur. J. Cancer"},{"issue":"17","key":"10.1016\/j.semcancer.2025.10.003_bib216","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.1093\/cvr\/cvac020","article-title":"Side effects of statins: from pathophysiology and epidemiology to diagnostic and therapeutic implications","volume":"118","author":"Ruscica","year":"2023","journal-title":"Cardiovasc Res"},{"issue":"1","key":"10.1016\/j.semcancer.2025.10.003_bib217","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1472-8206.2004.00299.x","article-title":"Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update","volume":"19","author":"Schachter","year":"2005","journal-title":"Fundam. Clin. Pharm."},{"key":"10.1016\/j.semcancer.2025.10.003_bib218","series-title":"Pitavastatin, StatPearls, StatPearls publishing copyright \u00a9 2025","author":"Bhatti","year":"2025"},{"issue":"23","key":"10.1016\/j.semcancer.2025.10.003_bib219","doi-asserted-by":"crossref","first-page":"5748","DOI":"10.1039\/D4NA00808A","article-title":"Nanomedicine marvels: crafting the future of cancer therapy with innovative statin nano-formulation strategies","volume":"6","author":"Karimi Jirandehi","year":"2024","journal-title":"Nanoscale Adv."},{"issue":"6","key":"10.1016\/j.semcancer.2025.10.003_bib220","doi-asserted-by":"crossref","first-page":"C1208","DOI":"10.1152\/ajpcell.00226.2006","article-title":"Statin-induced apoptosis and skeletal myopathy","volume":"291","author":"Dirks","year":"2006","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.semcancer.2025.10.003_bib221","first-page":"559","article-title":"Effect of statins on breast cancer recurrence and mortality: a review, breast cancer (Dove","volume":"9","author":"Van Wyhe","year":"2017","journal-title":"Med Press)"},{"key":"10.1016\/j.semcancer.2025.10.003_bib222","doi-asserted-by":"crossref","first-page":"5837","DOI":"10.2147\/IJN.S466042","article-title":"Tumor Cell-Targeting and tumor Microenvironment-Responsive nanoplatforms for the multimodal Imaging-Guided Photodynamic\/Photothermal\/Chemodynamic treatment of cervical cancer","volume":"19","author":"Wang","year":"2024","journal-title":"Int J. Nanomed."},{"key":"10.1016\/j.semcancer.2025.10.003_bib223","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.122899","article-title":"Nanoparticles in cancer theragnostic and drug delivery: a comprehensive review","volume":"352","author":"Al-Thani","year":"2024","journal-title":"Life Sci."},{"key":"10.1016\/j.semcancer.2025.10.003_bib224","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.semcancer.2019.09.025","article-title":"Challenges and pitfalls in the development of liposomal delivery systems for cancer therapy","volume":"69","author":"Moosavian","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.semcancer.2025.10.003_bib225","doi-asserted-by":"crossref","DOI":"10.1016\/j.eurpolymj.2021.110683","article-title":"Poly (propylene imine) dendrimer as an emerging polymeric nanocarrier for anticancer drug and gene delivery","volume":"158","author":"Singh","year":"2021","journal-title":"Eur. Polym. J."},{"key":"10.1016\/j.semcancer.2025.10.003_bib226","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.687585","article-title":"Hydrophilic or lipophilic statins?","volume":"8","author":"Climent","year":"2021","journal-title":"Front Cardiovasc Med"},{"issue":"6","key":"10.1016\/j.semcancer.2025.10.003_bib227","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1021\/acs.molpharmaceut.9b01117","article-title":"In vitro Blood-Brain barrier permeability and cytotoxicity of an Atorvastatin-Loaded nanoformulation against glioblastoma in 2D and 3D models","volume":"17","author":"L\u00fcbtow","year":"2020","journal-title":"Mol. Pharm."},{"issue":"6","key":"10.1016\/j.semcancer.2025.10.003_bib228","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1080\/01443615.2022.2033964","article-title":"Simvastatin-loaded liposome nanoparticles treatment for uterine leiomyoma in a patient-derived xenograft mouse model: a pilot study","volume":"42","author":"Sabeh","year":"2022","journal-title":"J. Obstet. Gynaecol."},{"issue":"2","key":"10.1016\/j.semcancer.2025.10.003_bib229","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15020369","article-title":"Co-Encapsulation of simvastatin and doxorubicin into pH-Sensitive liposomes enhances antitumoral activity in breast cancer cell lines","volume":"15","author":"Duarte","year":"2023","journal-title":"Pharmaceutics"},{"issue":"10","key":"10.1016\/j.semcancer.2025.10.003_bib230","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13101526","article-title":"A screening study for the development of Simvastatin-Doxorubicin liposomes, a Co-Formulation with future perspectives in colon cancer therapy","volume":"13","author":"Barb\u0103lat\u0103","year":"2021","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.semcancer.2025.10.003_bib231","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1080\/10837450.2018.1474221","article-title":"Preparation of biocompatible copolymeric micelles as a carrier of atorvastatin and rosuvastatin for potential anticancer activity study","volume":"24","author":"Hamidreza Kheiri","year":"2019","journal-title":"Pharm. Dev. Technol."},{"issue":"20","key":"10.1016\/j.semcancer.2025.10.003_bib232","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1016\/j.jacc.2016.02.071","article-title":"Statin-Associated side effects","volume":"67","author":"Thompson","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"issue":"6","key":"10.1016\/j.semcancer.2025.10.003_bib233","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovasc Drugs Ther."},{"issue":"3","key":"10.1016\/j.semcancer.2025.10.003_bib234","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jacl.2012.03.003","article-title":"Understanding statin use in america and gaps in patient education (USAGE): an Internet-based survey of 10,138 current and former statin users","volume":"6","author":"Cohen","year":"2012","journal-title":"J. Clin. Lipido"},{"issue":"4","key":"10.1016\/j.semcancer.2025.10.003_bib235","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/clpt.2014.121","article-title":"Phenotype standardization for statin-induced myotoxicity","volume":"96","author":"Alfirevic","year":"2014","journal-title":"Clin. Pharm. Ther."},{"key":"10.1016\/j.semcancer.2025.10.003_bib236","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.phrs.2015.07.008","article-title":"Lipid, G. Blood pressure Meta-analysis collaboration, statin therapy and plasma coenzyme Q10 concentrations--A systematic review and meta-analysis of placebo-controlled trials","volume":"99","author":"Banach","year":"2015","journal-title":"Pharm. Res"},{"issue":"9","key":"10.1016\/j.semcancer.2025.10.003_bib237","doi-asserted-by":"crossref","DOI":"10.1111\/1756-185X.15337","article-title":"Statin-associated muscle symptoms: a comprehensive exploration of epidemiology, pathophysiology, diagnosis, and clinical management strategies","volume":"27","author":"Shah","year":"2024","journal-title":"Int. J. Rheum. Dis."},{"issue":"21","key":"10.1016\/j.semcancer.2025.10.003_bib238","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222111687","article-title":"Statin-Associated myopathy: emphasis on mechanisms and targeted therapy","volume":"22","author":"Vinci","year":"2021","journal-title":"Int J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.semcancer.2025.10.003_bib239","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1161\/CIRCRESAHA.118.312782","article-title":"Statin toxicity","volume":"124","author":"Ward","year":"2019","journal-title":"Circ. Res"},{"issue":"10","key":"10.1016\/j.semcancer.2025.10.003_bib240","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.numecd.2014.05.009","article-title":"Resistance and intolerance to statins","volume":"24","author":"Reiner","year":"2014","journal-title":"Nutr. Metab. Cardiovasc Dis."},{"issue":"9","key":"10.1016\/j.semcancer.2025.10.003_bib241","first-page":"1410","article-title":"Predictors of nonadherence to statins: a systematic review and meta-analysis","volume":"44","author":"Mann","year":"2010","journal-title":"Ann. Pharm."},{"issue":"6","key":"10.1016\/j.semcancer.2025.10.003_bib242","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.amjcard.2005.09.134","article-title":"Phenotypic predictors of response to simvastatin therapy among African-Americans and caucasians: the cholesterol and pharmacogenetics (CAP) study","volume":"97","author":"Simon","year":"2006","journal-title":"Am. J. Cardiol."},{"issue":"2","key":"10.1016\/j.semcancer.2025.10.003_bib243","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1161\/ATVBAHA.113.301301","article-title":"Inflammatory stress induces statin resistance by disrupting 3-hydroxy-3-methylglutaryl-CoA reductase feedback regulation","volume":"34","author":"Chen","year":"2014","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"9","key":"10.1016\/j.semcancer.2025.10.003_bib244","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1161\/ATVBAHA.109.188474","article-title":"Identification of genetic variants associated with response to statin therapy","volume":"29","author":"Mega","year":"2009","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"8","key":"10.1016\/j.semcancer.2025.10.003_bib245","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","article-title":"SLCO1B1 variants and statin-induced myopathy--a genomewide study","volume":"359","author":"Link","year":"2008","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.semcancer.2025.10.003_bib246","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2024.149841","article-title":"Overcoming statin resistance in prostate cancer cells by targeting the 3-hydroxy-3-methylglutaryl-CoA-reductase","volume":"710","author":"G\u00f6bel","year":"2024","journal-title":"Biochem Biophys. Res Commun."},{"issue":"2","key":"10.1016\/j.semcancer.2025.10.003_bib247","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41419-019-1322-x","article-title":"Induction of 3-hydroxy-3-methylglutaryl-CoA reductase mediates statin resistance in breast cancer cells","volume":"10","author":"G\u00f6bel","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.semcancer.2025.10.003_bib248","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1200\/EDBK_174176","article-title":"Precision oncology: who, how, what, when, and when not?","volume":"37","author":"Schwartzberg","year":"2017","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.semcancer.2025.10.003_bib249","unstructured":"Personalized medicine: identifying the appropriate patient through biomarkers in oncology, P T ,2011, 36(7 Suppl 1) pp. 3-10."},{"issue":"6","key":"10.1016\/j.semcancer.2025.10.003_bib250","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.trecan.2020.11.008","article-title":"Targeting the mevalonate pathway in cancer","volume":"7","author":"Juarez","year":"2021","journal-title":"Trends Cancer"},{"issue":"4","key":"10.1016\/j.semcancer.2025.10.003_bib251","first-page":"341","article-title":"Influence of pharmacogenetics on the diversity of response to statins associated with adverse drug reactions","volume":"4","author":"Sainz de Medrano Sainz","year":"2023","journal-title":"Adv. Lab Med"},{"issue":"19","key":"10.1016\/j.semcancer.2025.10.003_bib252","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1093\/jnci\/djr291","article-title":"Statin prescriptions and breast cancer recurrence risk: a danish nationwide prospective cohort study","volume":"103","author":"Ahern","year":"2011","journal-title":"J. Natl. Cancer Inst."},{"issue":"1","key":"10.1016\/j.semcancer.2025.10.003_bib253","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/EDE.0000000000000189","article-title":"Statin use after diagnosis of breast cancer and survival: a population-based cohort study","volume":"26","author":"Cardwell","year":"2015","journal-title":"Epidemiology"},{"issue":"1","key":"10.1016\/j.semcancer.2025.10.003_bib254","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.canep.2013.10.010","article-title":"Statin use and risk of prostate cancer: a danish population-based case-control study, 1997-2010","volume":"38","author":"Jespersen","year":"2014","journal-title":"Cancer Epidemiol."},{"issue":"5","key":"10.1016\/j.semcancer.2025.10.003_bib255","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1158\/1078-0432.CCR-19-2853","article-title":"Statin use is associated with lower risk of PTEN-Null and lethal prostate cancer","volume":"26","author":"Allott","year":"2020","journal-title":"Clin. Cancer Res"},{"issue":"2","key":"10.1016\/j.semcancer.2025.10.003_bib256","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/aogs.13069","article-title":"Statin use and risk of endometrial cancer: a nationwide registry-based case-control study","volume":"96","author":"Sperling","year":"2017","journal-title":"Acta Obstet. Gynecol. Scand."},{"issue":"1","key":"10.1016\/j.semcancer.2025.10.003_bib257","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1158\/1940-6207.CAPR-20-0123","article-title":"Association of aspirin, metformin, and statin use with gastric cancer incidence and mortality: a nationwide cohort study","volume":"14","author":"Cho","year":"2021","journal-title":"Cancer Prev Res (Phila)"},{"key":"10.1016\/j.semcancer.2025.10.003_bib258","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.lungcan.2018.10.022","article-title":"Statins associate with improved mortality among patients with certain histological subtypes of lung cancer","volume":"126","author":"Ung","year":"2018","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.semcancer.2025.10.003_bib259","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/bjc.2016.149","article-title":"Statin use and all-cancer survival: prospective results from the women's health initiative","volume":"115","author":"Wang","year":"2016","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.semcancer.2025.10.003_bib260","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00280-013-2328-1","article-title":"Randomized double-blinded, placebo-controlled phase II trial of simvastatin and gemcitabine in advanced pancreatic cancer patients","volume":"73","author":"Hong","year":"2014","journal-title":"Cancer Chemother. Pharm."},{"issue":"16","key":"10.1016\/j.semcancer.2025.10.003_bib261","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1016\/j.ejca.2014.08.005","article-title":"Simvastatin plus capecitabine-cisplatin versus placebo plus capecitabine-cisplatin in patients with previously untreated advanced gastric cancer: a double-blind randomised phase 3 study","volume":"50","author":"Kim","year":"2014","journal-title":"Eur. J. Cancer"},{"issue":"6","key":"10.1016\/j.semcancer.2025.10.003_bib262","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1158\/1078-0432.CCR-10-2525","article-title":"A randomized phase II study of gefitinib plus simvastatin versus gefitinib alone in previously treated patients with advanced non-small cell lung cancer","volume":"17","author":"Han","year":"2011","journal-title":"Clin. Cancer Res"},{"issue":"4","key":"10.1016\/j.semcancer.2025.10.003_bib263","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.4143\/crt.2016.546","article-title":"Randomized phase II study of afatinib plus simvastatin versus afatinib alone in previously treated patients with advanced nonadenocarcinomatous Non-small cell lung cancer","volume":"49","author":"Lee","year":"2017","journal-title":"Cancer Res Treat."},{"issue":"3","key":"10.1016\/j.semcancer.2025.10.003_bib264","doi-asserted-by":"crossref","first-page":"885","DOI":"10.4143\/crt.2023.283","article-title":"A randomized phase II study of irinotecan plus cisplatin with or without simvastatin in Ever-Smokers with extended disease small cell lung cancer","volume":"55","author":"Lee","year":"2023","journal-title":"Cancer Res Treat."},{"issue":"7","key":"10.1016\/j.semcancer.2025.10.003_bib265","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1054\/bjoc.2000.1716","article-title":"Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial","volume":"84","author":"Kawata","year":"2001","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.semcancer.2025.10.003_bib266","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jhep.2019.04.021","article-title":"P.-. Investigators\/collaborators, pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma","volume":"71","author":"Jouve","year":"2019","journal-title":"J. Hepatol."},{"issue":"18","key":"10.1016\/j.semcancer.2025.10.003_bib267","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1016\/j.ejca.2010.07.036","article-title":"The addition of pravastatin to chemotherapy in advanced gastric carcinoma: a randomised phase II trial","volume":"46","author":"Konings","year":"2010","journal-title":"Eur. J. Cancer"},{"issue":"14","key":"10.1016\/j.semcancer.2025.10.003_bib268","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1200\/JCO.2016.69.7391","article-title":"Multicenter, phase III, randomized, Double-Blind, Placebo-Controlled trial of pravastatin added to First-Line standard chemotherapy in Small-Cell lung cancer (LUNGSTAR)","volume":"35","author":"Seckl","year":"2017","journal-title":"J. Clin. Oncol."}],"container-title":["Seminars in Cancer Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X25001282?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X25001282?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T08:08:22Z","timestamp":1765094902000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044579X25001282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":268,"alternative-id":["S1044579X25001282"],"URL":"https:\/\/doi.org\/10.1016\/j.semcancer.2025.10.003","relation":{},"ISSN":["1044-579X"],"issn-type":[{"value":"1044-579X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond cardiovascular health: The pharmacotherapeutic potential of statins in oncology","name":"articletitle","label":"Article Title"},{"value":"Seminars in Cancer Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semcancer.2025.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}